GSK
As of the edition of 20 October 2026, GSK runs 530 drugs, 177 of them marketed; it is on route A at 90 targets and on route B at 58 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
GSK was renamed in 2008.
The records place 26 company names in this family.
- Smithkline Beecham Corp Dba Glaxosmithkline: acquired in 2000; successor GLAXOSMITHKLINE
- GLAXOSMITHKLINE: renamed in 2008
- Human Genome Sciences Inc.: acquired in 2012
- Tesaro, Inc.: acquired in 2019
- GlaxoSmithKline Trading Services Limited: acquired in 2023; successor GLAXOSMITHKLINE
- Corixa Corporation: acquired in 2025; successor GLAXOSMITHKLINE
- GlaxoSmithKline Biologicals: acquired in 2025; successor GLAXOSMITHKLINE
- RAPT Therapeutics, Inc.: acquired in 2026; successor GLAXOSMITHKLINE
- Nuvalent Inc.: acquired in 2026; successor GLAXOSMITHKLINE
Drugs by status
| Status | Count |
|---|---|
| Marketed | 177 |
| Active | 52 |
| Went quiet | 185 |
| Stopped | 98 |
| Withdrawn from market | 1 |
| Status not established | 17 |
| Total | 530 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Leucovorin | none listed | 0 |
| Melphalan | none listed | 0 |
| Busulfan | none listed | 0 |
| Nicotine | none listed | 1 |
| Lamivudine | none listed | 0 |
| Amoxicillin | none listed | 0 |
| Sodium chloride | none listed | 0 |
| Zidovudine | none listed | 0 |
| Vinorelbine | none listed | 8 |
| Tenofovir disoproxil | none listed | 0 |
| Topotecan | none listed | 1 |
| Botulinum toxin type a | none listed | 2 |
| Remifentanil | none listed | 1 |
| Bupropion | none listed | 2 |
| Trametinib | Ends 2030 (patent) | 2 |
| Albuterol | none listed | 2 |
| Ondansetron | none listed | 0 |
| Lapatinib | Ends 2029 (patent) | 2 |
| Pazopanib | none listed | 5 |
| Niraparib | Ends 2031 (patent) | 6 |
| Mercaptopurine anhydrous | none listed | 1 |
| Dolutegravir | Ends 2031 (patent) | 0 |
| Fluticasone propionate | none listed | 2 |
| Digoxin | none listed | 0 |
| Dabrafenib | Ends 2030 (patent) | 1 |
A route B row is one company at one target. 152 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 90 targets, route B at 58 targets.
All 148 rows on route A or B
In the product148 company-target rows on route A or B; 145 are not shown here, and no score is.
See all 148 targets where GSK needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Immune system: 557 trials led
- Infections: 522 trials led
- Urinary and reproductive: 418 trials led